生物海洋制药公司在超出预期的收益后获得"中等购买"评级. BioMarin Pharmaceutical receives "Moderate Buy" rating after beating earnings expectations.

开发稀有疾病的治疗方法的生物海洋制药公司从分析家那里获得了“机动购买”评级,平均12个月的价格目标是94.00美元。 BioMarin Pharmaceutical Inc., which develops therapies for rare diseases, received a "Moderate Buy" rating from analysts, with an average 12-month price target of $94.00. 该公司的最新收入报告击败了预期,EPS为0.72美元,超过0.54美元的一致估计。 The company's latest earnings report beat expectations, with an EPS of $0.72, surpassing the consensus estimate of $0.54. BioMarin 的市值为 134.5 亿美元。 BioMarin's market cap is $13.45 billion.